Traditional Chinese medicine is one of the characteristics of Chinese medicine, in recent years, in the domestic vigorous development of the traditional Chinese medicine industry, accelerate the speed of approval of traditional Chinese medicine innovative drugs, and traditional Chinese medicine innovative drugs and exclusive varieties in the medical insurance centralized procurement of the background of greater competitive advantage, many pharmaceutical companies have taken traditional Chinese medicine innovative drugs as the company's development focus
.
At the same time, the field of innovative traditional Chinese medicine has also begun to usher in more and more new breakthroughs
.
Long-term opportunities for the innovative industry of traditional Chinese medicine have emerged! A large number of enterprises will benefit (Image source: Pharma Network)
For example, on December 29, 2022, the State Medical Products Administration approved the listing of ginseng kazu kidney tonic capsules of traditional Chinese medicine class 1.
1 declared by Xinjiang Huachun Biopharmaceutical; on September 29, Jianmin Pharmaceutical's marketing application for class 1.
1 Chinese proprietary medicine Pediatric Purple Shell cough syrup was accepted by CDE, which is the sixth innovative drug of traditional Chinese medicine declared for marketing this year; in addition, Renfu Pharmaceutical's class 1.
2 new drug Guangqian Grass Total Flavonoid Capsules has also been approved for marketing, which is Renfu Pharmaceutical's follow-up to the class 1 chemical drug remazolam besylate, After phosphopofol disodium is approved, it is the third Class 1 innovative drug approved, and it is also the first Class 1 new drug of traditional Chinese medicine of Renfu Pharmaceutical.
.
.
Industry analysts believe that from the policy to encourage traditional Chinese medicine innovation from the approval side, to the payment side, listed traditional Chinese medicine innovative drugs are also supported by medical insurance and other policies, long-term opportunities for traditional Chinese medicine innovative drugs are emerging, and many enterprises in the industrial chain will usher in more benefits
.
In fact, according to the combing, many companies have already said that they have adhered to the innovative research and development of traditional Chinese medicine, as well as the innovation of core products of traditional Chinese medicine, and achieved growth in performance
.
For example, Fangsheng Pharmaceutical said in the third-quarter performance report released on the evening of October 30 last year that its performance has reached a record high
thanks to its continuous focus on the main business of innovative traditional Chinese medicine in recent years.
In the first three quarters, Fangsheng Pharmaceutical achieved a year-on-year increase of 21.
99% in operating income of 1.
357 billion yuan, and a year-on-year increase in net profit attributable to shareholders of listed companies of 317.
50% to 259 million yuan
.
Wellcome Pharmaceutical also said that it attaches great importance to the R&D and innovation of traditional Chinese medicine, and achieved operating income of 474 million yuan in the first three quarters of 2022, and net profit attributable to the parent of 94 million yuan, a year-on-year increase of 1.
31%.
In the third quarter, the operating income was 179 million yuan, a year-on-year increase of 5.
39%, a month-on-month increase of 59.
81%, and the net profit attributable to the parent was 37 million yuan, a year-on-year increase of 27.
63% and a month-on-month increase of 8.
45%.
At present, on the whole, more and more pharmaceutical companies have embarked on the road
of accelerated development through innovation.
It is worth noting that many of these companies are also accelerating the use of new technologies and platforms such as artificial intelligence, big data, and electronic data collection to accelerate the efficiency of drug research and development and further promote the process of clinical trials.
.
.
Tasly has actively embraced digital transformation and has built two key laboratories: "State Key Laboratory of Key Technologies of Innovative Chinese Medicine" and "National and Local Joint Engineering Laboratory of Advanced Manufacturing Technology of Traditional Chinese Medicine"
.
In addition, Yunnan Baiyao has also created a "digital three-seven industrial platform"
through the use of 5G, industrial Internet, big data, artificial intelligence, blockchain and other technologies.
It is worth mentioning that Yunnan Baiyao also said at the investor research conference that it will develop and transform
around the "1+4+1" strategy.
Among them, in terms of digitalization, new technologies, including artificial intelligence, will be introduced into all aspects of R&D and operation, so that development has a higher starting point
.
The industry expects that in the future, with the deep integration and innovation of new technologies and traditional Chinese medicine, the traditional industry of traditional Chinese medicine will "blossom new trees", usher in more innovative achievements, and enter a higher quality development stage
.
It should be noted that under the great innovation and development of the traditional Chinese medicine industry, there are still many challenges in the traditional Chinese medicine industry in terms of innovation, such as the difficulty of innovation, the general face of unclear mechanism of action and unclear active ingredients in research and development
.
Among them, in the research and development and production links, traditional Chinese medicine is inseparable from the support
of higher quality and more precise instruments and production equipment.
Therefore, in the context of the acceleration of innovation of traditional Chinese medicine enterprises, China's pharmaceutical equipment industry also needs to continuously develop and produce higher-quality instruments and equipment to meet the needs of
innovation and development.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
